Janux Therapeutics (JANX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to -$0.39.
- Janux Therapeutics' EPS (Weighted Average and Diluted) rose 2352.94% to -$0.39 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year decrease of 4396.55%. This contributed to the annual value of -$1.28 for FY2024, which is 275.95% up from last year.
- Janux Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.39 in Q3 2025, which was up 2352.94% from -$0.55 recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.11 during Q2 2024, and its lowest value of -$0.62 during Q2 2021.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.37, with a median of -$0.38 in 2025.
- As far as peak fluctuations go, Janux Therapeutics' EPS (Weighted Average and Diluted) surged by 7380.95% in 2024, and later plummeted by 40000.0% in 2025.
- Janux Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.29 in 2021, then tumbled by 34.48% to -$0.39 in 2022, then soared by 38.46% to -$0.24 in 2023, then tumbled by 56.71% to -$0.38 in 2024, then dropped by 3.7% to -$0.39 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.39 in Q3 2025, compared to -$0.55 in Q2 2025 and -$0.38 in Q1 2025.